Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Lymphoma

CRL3–SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-κB signaling

Leukemia volume 34, pages 1305–1314 (2020)Cite this article

Subjects

Abstract

Recurrent oncogenic mutations of MyD88 have been identified in a variety of lymphoid malignancies. Gain-of-function mutations of MyD88 constitutively activate downstream NF-κB signaling pathways, resulting in increased cellular proliferation and survival. However, whether MyD88 activity can be aberrantly regulated in MyD88-wild-type lymphoid malignancies remains poorly understood. SPOP is an adaptor protein of CUL3-based E3 ubiquitin ligase complex and frequently mutated genes in prostate and endometrial cancers. In this study, we reveal that SPOP binds to and induces the nondegradative ubiquitination of MyD88 by recognizing an atypical SPOP-binding motif in MyD88. This modification blocks Myddosome assembly and downstream NF-κB activation. SPOP is mutated in a subset of lymphoid malignancies, including diffuse large B-cell lymphoma (DLBCL). Lymphoid malignancies-associated SPOP mutants exhibited impaired binding to MyD88 and suppression of NF-κB activation. The DLBCL-associated, SPOP-binding defective mutants of MyD88 escaped from SPOP-mediated ubiquitination, and their effect on NF-κB activation is stronger than that of wild-type MyD88. Moreover, SPOP suppresses DLBCL cell growth in vitro and tumor xenograft in vivo by inhibiting the MyD88/NF-κB signaling. Therefore, SPOP acts as a tumor suppressor in DLBCL. Mutations in the SPOP–MyD88 binding interface may disrupt the SPOP–MyD88 regulatory axis and promote aberrant MyD88/NF-κB activation and cell growth in DLCBL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Yu X, Li W, Deng Q, Li L, Hsi ED, Young KH, et al. MYD88 L265P mutation in lymphoid malignancies. Cancer Res. 2018;78:2457–62.

    Article  CAS  Google Scholar 

  2. Grondona P, Bucher P, Schulze-Osthoff K, Hailfinger S, Schmitt A. NF-kappaB activation in lymphoid malignancies: genetics, signaling, and targeted therapy. Biomedicines. 2018;6:38.

  3. Krappmann D, Vincendeau M. Mechanisms of NF-kappaB deregulation in lymphoid malignancies. Semin Cancer Biol. 2016;39:3–14.

    Article  CAS  Google Scholar 

  4. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010;327:291–5.

    Article  CAS  Google Scholar 

  5. Lin SC, Lo YC, Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature. 2010;465:85–90.

    Article  CAS  Google Scholar 

  6. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115–9.

    Article  CAS  Google Scholar 

  7. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med. 2012;367:826–33.

    Article  CAS  Google Scholar 

  8. Landgren O, Staudt L. MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med. 2012;367:2255–6.

    Article  CAS  Google Scholar 

  9. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475:101–5.

    Article  CAS  Google Scholar 

  10. Avbelj M, Wolz OO, Fekonja O, Bencina M, Repic M, Mavri J, et al. Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization. Blood. 2014;124:3896–904.

    Article  CAS  Google Scholar 

  11. Zhuang M, Calabrese MF, Liu J, Waddell MB, Nourse A, Hammel M, et al. Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. Mol Cell. 2009;36:39–50.

    Article  CAS  Google Scholar 

  12. Li C, Ao J, Fu J, Lee DF, Xu J, Lonard D, et al. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Oncogene. 2011;30:4350–64.

    Article  CAS  Google Scholar 

  13. An J, Wang C, Deng Y, Yu L, Huang H. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep. 2014;6:657–69.

    Article  CAS  Google Scholar 

  14. Zhang P, Gao K, Jin X, Ma J, Peng J, Wumaier R, et al. Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-alpha protein turnover. Cell Death Dis. 2015;6:e1687.

    Article  CAS  Google Scholar 

  15. Theurillat JP, Udeshi ND, Errington WJ, Svinkina T, Baca SC, Pop M, et al. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science. 2014;346:85–9.

    Article  CAS  Google Scholar 

  16. An J, Ren S, Murphy SJ, Dalangood S, Chang C, Pang X, et al. Truncated ERG oncoproteins from TMPRSS2-ERG fusions are resistant to SPOP-mediated proteasome degradation. Mol Cell. 2015;59:904–16.

    Article  CAS  Google Scholar 

  17. Gan W, Dai X, Lunardi A, Li Z, Inuzuka H, Liu P, et al. SPOP promotes ubiquitination and degradation of the ERG oncoprotein to suppress prostate cancer progression. Mol Cell. 2015;59:917–30.

    Article  CAS  Google Scholar 

  18. Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553:91–5.

    Article  CAS  Google Scholar 

  19. Janouskova H, El Tekle G, Bellini E, Udeshi ND, Rinaldi A, Ulbricht A, et al. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat Med. 2017;23:1046–54.

    Article  CAS  Google Scholar 

  20. Zhang P, Wang D, Zhao Y, Ren S, Gao K, Ye Z, et al. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat Med. 2017;23:1055–62.

    Article  CAS  Google Scholar 

  21. Jin X, Wang J, Gao K, Zhang P, Yao L, Tang Y, et al. Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer. PLoS Genet. 2017;13:e1006748.

    Article  Google Scholar 

  22. Hernandez-Munoz I, Lund AH, van der Stoop P, Boutsma E, Muijrers I, Verhoeven E, et al. Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase. Proc Natl Acad Sci USA. 2005;102:7635–40.

    Article  CAS  Google Scholar 

  23. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44:685–9.

    Article  CAS  Google Scholar 

  24. Le Gallo M, O’Hara AJ, Rudd ML, Urick ME, Hansen NF, O’Neil NJ, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet. 2012;44:1310–5.

    Article  Google Scholar 

  25. Huttlin EL, Bruckner RJ, Paulo JA, Cannon JR, Ting L, Baltier K, et al. Architecture of the human interactome defines protein communities and disease networks. Nature. 2017;545:505–9.

    Article  CAS  Google Scholar 

  26. Kagan JC, Medzhitov R. Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell. 2006;125:943–55.

    Article  CAS  Google Scholar 

  27. Zhao Y, Mudge MC, Soll JM, Rodrigues RB, Byrum AK, Schwarzkopf EA, et al. OTUD4 is a phospho-activated K63 deubiquitinase that regulates MyD88-dependent signaling. Mol Cell. 2018;69:505–16 e505.

    Article  CAS  Google Scholar 

  28. Lee BC, Miyata M, Lim JH, Li JD. Deubiquitinase CYLD acts as a negative regulator for bacterium NTHi-induced inflammation by suppressing K63-linked ubiquitination of MyD88. Proc Natl Acad Sci USA. 2016;113:E165–71.

    Article  CAS  Google Scholar 

  29. Guillamot M, Ouazia D, Dolgalev I, Yeung ST, Kourtis N, Dai Y, et al. The E3 ubiquitin ligase SPOP controls resolution of systemic inflammation by triggering MYD88 degradation. Nat Immunol. 2019;20:1196–207.

    Article  CAS  Google Scholar 

  30. Yao S, Chen X, Chen J, Guan Y, Liu Y, Chen J, et al. Speckle-type POZ protein functions as a tumor suppressor in non-small cell lung cancer due to DNA methylation. Cancer Cell Int. 2018;18:213.

    Article  CAS  Google Scholar 

  31. Zhi X, Tao J, Zhang L, Tao R, Ma L, Qin J. Silencing speckle-type POZ protein by promoter hypermethylation decreases cell apoptosis through upregulating Hedgehog signaling pathway in colorectal cancer. Cell Death Dis. 2016;7:e2569.

    Article  CAS  Google Scholar 

  32. Jais JP, Haioun C, Molina TJ, Rickman DS, de Reynies A, Berger F, et al. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia. 2008;22:1917–24.

    Article  CAS  Google Scholar 

  33. Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell. 2013;24:777–90.

    Article  CAS  Google Scholar 

  34. Atanackovic D, Luetkens T. Biomarkers for checkpoint inhibition in hematologic malignancies. Semin Cancer Biol. 2018;52:198–206.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Natural Science Foundation of China (81972396, 81672558, and 81201533 to CW; 81572768 to XJ; 31400753, 81872109 to KG; 81572768, 81872260 to PZ), the Natural Science Foundation of Zhejiang Province (LY20C070001 to XJ), the Natural Science Foundation of Ningbo (2018A610213 to XJ), the National Undergraduate Training Program for Innovation and Entrepreneurship (201811646022 to LZ), the Student Research and Innovation Program of Ningbo University (2018SRIP1925 to QL) and the KC Wong Magna Fund in Ningbo University.

Author information

Author notes

  1. These authors contributed equally: Xiaofeng Jin, Qing Shi

Authors and Affiliations

  1. Department of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Medical School of Ningbo University, Ningbo, 315211, China

    Xiaofeng Jin, Qian Li, Jian Wang, Lei Jiang, Ting Lin, Zihan Lin, Hui Zhuang, Jianye Yang, Chongke Hu, Luyi Zhang, Xiaodan Meng, Yang Xi, Jinchang Pan, Shuai Fang, Haihua Tian & Zhaohui Gong

  2. State Key Laboratory of Genetic Engineering, MOE Engineering Research Center of Gene Technology, Key Laboratory of Reproduction Regulation of NPFPC and Collaborative Innovation Center for Genetics and Development, Fudan University, Shanghai, 200438, China

    Qing Shi, Xiaying Zhao, Kai Feng, Shi-min Zhao, Yao Li & Chenji Wang

  3. Department of Science, National University of Singapore, Singapore, 117543, Singapore

    Linyi Zhou

  4. Department of Urology, Department of Hematology, The Affiliated Yinzhou Renmin Hospital of Medical School of Ningbo University, Ningbo, 315040, China

    Liliang Shen & Ying Lu

  5. Department of hepato-biliary-pancreatic Surgery, The Affiliated Ningbo Medical Center of LiHuiLi Hospital of Medical School of Ningbo University, Ningbo, 315048, China

    Jie Zhu & Haibiao Wang

  6. Department of Urology, The Affiliated Yinzhou Second Hospital of Medical School of Ningbo University, Ningbo, 315100, China

    Honggang Qi

  7. Department of Thoracic Surgery, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, 315020, China

    Chengwei Zhou

  8. Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, China

    Pingzhao Zhang

  9. Clinical and Translational Research Center, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, 200040, China

    Kun Gao

Authors
  1. Xiaofeng Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qing Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qian Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Linyi Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jian Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lei Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiaying Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kai Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ting Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Zihan Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hui Zhuang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jianye Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Chongke Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Luyi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Liliang Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Ying Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Jie Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Haibiao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Honggang Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Xiaodan Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Yang Xi
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Jinchang Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Shuai Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Haihua Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Chengwei Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Pingzhao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. Kun Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. Shi-min Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. Yao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. Zhaohui Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  31. Chenji Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chenji Wang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jin, X., Shi, Q., Li, Q. et al. CRL3–SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-κB signaling. Leukemia 34, 1305–1314 (2020). https://doi.org/10.1038/s41375-019-0661-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-019-0661-z

This article is cited by

Search

Advanced search

Quick links